rotation.to
Following this device: dark.
Free account
rotation.to
Appearance
Following this device: dark.
Drag a card by its title · ⚙ to size, swap or remove

Who

Jennifer Bush

COO, CLO, Compliance Officer

Company insider

Files Form 4 as: COO, CLO, Compliance Officer, Artiva Biotherapeutics; General Counsel & Secretary, VivoSim Labs.

In numbers

Trades disclosed
49
Buys
0
Sells
3
Bought
$0
Sold
$403K
Companies
2
Companies where not an officer
0
First trade
6 Nov 2014
Last trade
5 Oct 2026
Last filed
6 Oct 2026

Companies traded

Where they are an officer
ARTV Artiva BiotherapeuticsOfficer · Biotechnology · last 5 Oct 20260 buys · 3 sells
VIVS VivoSim LabsOfficer · Biotechnology · last 18 Aug 20200 buys · 0 sells

Activity over time

1 May – 1 Oct
10May 26Jun 26Aug 26Sep 26Oct 26

Buys above the line, sells below, each month.

Every trade

TradedCompanyWhatAmount
5 Oct 2026filed 6 Oct 2026ARTV Artiva BiotherapeuticsBiotechnologySEC FORM 4 Sold$57K8,370 at $6.84filing
9 Sep 2026filed 11 Sep 2026ARTV Artiva BiotherapeuticsBiotechnologySEC FORM 4 Code A—45,000 at $0.00filing
9 Sep 2026filed 11 Sep 2026ARTV Artiva Biotherapeuticsoption or derivative · BiotechnologySEC FORM 4 Code A—135,000 at $0.00filing
9 Sep 2026filed 11 Sep 2026ARTV Artiva Biotherapeuticsoption or derivative · BiotechnologySEC FORM 4 Code A—135,000 at $0.00filing
9 Sep 2026filed 11 Sep 2026ARTV Artiva BiotherapeuticsBiotechnologySEC FORM 4 Code A—45,000 at $0.00filing
3 Sep 2026filed 4 Sep 2026ARTV Artiva BiotherapeuticsBiotechnologySEC FORM 4 Sold$94K8,391 at $11.16filing
3 Sep 2026filed 4 Sep 2026ARTV Artiva BiotherapeuticsBiotechnologySEC FORM 4 Sold$94K8,391 at $11.16filing
19 May 2026filed 19 May 2026ARTV Artiva BiotherapeuticsBiotechnologySEC FORM 4 Sold$79K8,790 at $9.01filing
19 May 2026filed 19 May 2026ARTV Artiva BiotherapeuticsBiotechnologySEC FORM 4 Sold$79K8,790 at $9.01filing
15 Feb 2026filed 18 Feb 2026ARTV Artiva BiotherapeuticsBiotechnologySEC FORM 4 Code A—117,300 at $0.00filing
15 Feb 2026filed 18 Feb 2026ARTV Artiva BiotherapeuticsBiotechnologySEC FORM 4 Code F$14K3,515 at $4.00filing
15 Feb 2026filed 18 Feb 2026ARTV Artiva BiotherapeuticsBiotechnologySEC FORM 4 Code A—117,300 at $0.00filing
15 Feb 2026filed 18 Feb 2026ARTV Artiva BiotherapeuticsBiotechnologySEC FORM 4 Code F$14K3,515 at $4.00filing
12 Dec 2025filed 12 Dec 2025ARTV Artiva Biotherapeuticsoption or derivative · BiotechnologySEC FORM 4 Code D—41,039filing
12 Dec 2025filed 12 Dec 2025ARTV Artiva Biotherapeuticsoption or derivative · BiotechnologySEC FORM 4 Code D—9,119filing
12 Dec 2025filed 12 Dec 2025ARTV Artiva Biotherapeuticsoption or derivative · BiotechnologySEC FORM 4 Code D—14,202filing
12 Dec 2025filed 12 Dec 2025ARTV Artiva Biotherapeuticsoption or derivative · BiotechnologySEC FORM 4 Code D—20,519filing
12 Dec 2025filed 12 Dec 2025ARTV Artiva BiotherapeuticsBiotechnologySEC FORM 4 Code A—84,877 at $0.00filing
15 Nov 2025filed 17 Nov 2025ARTV Artiva BiotherapeuticsBiotechnologySEC FORM 4 Code F$9,9293,055 at $3.25filing
15 Aug 2025filed 18 Aug 2025ARTV Artiva BiotherapeuticsBiotechnologySEC FORM 4 Code F$18K6,409 at $2.75filing

News

No headline names them, or the companies they trade most, lately.

Sectors

Health Care3

Buys in green, sells in red, by the company’s sector.

Related people

Fred AslanChief Executive Officer · Chief Executive Officer at Artiva Biotherapeutics, filing Form 4 there in the last year
Subhashis BanerjeeChief Medical Officer · Chief Medical Officer at Artiva Biotherapeutics, filing Form 4 there in the last year
Christopher HoranChief Tech Operations Officer · Chief Tech Operations Officer at Artiva Biotherapeutics, filing Form 4 there in the last year
RA CAPITAL MANAGEMENT, L.P.Director and 10% owner · Director and 10% owner at Artiva Biotherapeutics, filing Form 4 there in the last year
Alison MoorePresident and CEO · Director at Artiva Biotherapeutics, filing Form 4 there in the last year